MBK Partners’ Bid For AsiaPharm Nears Completion
This article was originally published in PharmAsia News
Executive Summary
AsiaPharm's delisting from the Singapore Stock Exchange in February this year has been strongly opposed by some shareholders but the situation could soon change. Martin Currie recently announced it has accepted MBK Partners' takeover offer and will transfer its 5.68 percent stake in AsiaPharm; Templeton Asset Management will also give the nod if MBK raises its bidding price from S$0.725 to S$0.9 per share. However, MBK stands by its current offer which, as of early May, has been accepted by about 77 percent of AsiaPharm's shareholders and the offer deadline of May 24 would not be extended. Industry analysts observe that AsiaPharm investors intend to use the firm as a platform to list its performing subsidiaries in future. (Click here for more - Chinese Language)
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.